Study Summary
This trial tests a new drug combo to treat advanced breast cancer.
- Breast Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 13 Secondary · Reporting Duration: 1.5 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Elacestrant / Onapristone
1 of 1
Experimental Treatment
67 Total Participants · 1 Treatment Group
Primary Treatment: Elacestrant / Onapristone · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there still vacancies for individuals wishing to participate in this examination?
"Affirmative. Information on clinicaltrials.gov suggests that this experiment is still recruiting participants, with the first posting occurring on November 22nd 2022 and an update made December 2nd of the same year. 67 patients are needed to be recruited from 1 centre." - Anonymous Online Contributor
What is the upper limit of participants for this experiment?
"Affirmative, the information posted to clinicaltrials.gov confirms that this medical trial is open for recruitment. It was first advertised on November 22nd 2022 and its details were most recently updated December 2nd of the same year. The study requires 67 participants from 1 centre." - Anonymous Online Contributor
What outcomes are researchers hoping to realize with this investigation?
"According to Context Therapeutics Inc., the main objective of this 9 month trial is to measure the efficacy of elacestrant in combination with onapristone, as measured by Objective Response Rate (ORR) per RECIST Version 1.1 (Phase 2). Additionally, secondary metrics such as overall survival rate, clinical benefit rate and progression-free survival will also be collected and analyzed." - Anonymous Online Contributor